Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

3154 MSK > Pharmaco: RA > Flashcards

Pharmaco: RA Flashcards

1
Q

List the drugs used in RA and their class

A

Anti-inflammatory agents:

  • NSAIDs (short-term pain relief)
  • Corticosteroids (low dose bridging therapy)

No role for paracetamol

Conventional Synthetic DMARD (csDMARD)

  • Methotraxate
  • Sulfasalazine
  • Leflunomide
  • Hydroxychloroquine
  • Ciclosporin

Targeted Synthetic DMARD (tsDMARD)

  • Tofacitinib
  • Baricitinib

Biologic DMARD (bDMARD)

  • Anti-TNF mAb: Infliximab, Adalimumab, Etanercept
  • IL-1R antagonist: Anakinra (NA in Sg)
  • Anti-CTLA4lg: Abatacept (NA in Sg)
  • Anti-CD20: Rituximab
  • Anti-IL6 receptor mAb: Tocilizumab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Side effects of glucocorticoids

A
  • Increase CVD risk
  • Cataract, glaucoma
  • Skin thinning, hirsutism
  • Gastric ulcer (if concomitant NSAID)
  • Weight gain, fluid retention, Cushing syndrome
  • Impaired glucose metabolism, insulin resistance, B-cell dysfunction
  • Neuro-psychiatric symptoms, HPA insufficiency
  • Osteonecrosis, osteoporosis
  • Myopathy
  • Infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

[csDMARD - Methotrexate]

Dosage forms

A
  • oral
  • SQ
  • IM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

[csDMARD - Methotrexate]

MOA

A

Major action:

  • Inhibits ATIC enzyme, thereby increasing adenosine levels, activation of adenosine A2a receptors results in anti-inflammatory effects:
  • antiproliferative effects on T cells
  • inhibition of macrophage functions
  • downregulation of pro-inflammatory cytokines, adhesion molecules, chemotaxis, phagocytosis

Minor action:

  • inhibits dihydrofolate reductase (DHFR) and thymidylate synthetase, decrease purine synthesis, affect cell replication
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

[csDMARD - Methotrexate]

Side effects

A
  • GI SEs: N/V/D, Anorexia, Mouth and GI ulcers (stomatitis)
  • Hair thinning
  • Liver: increase transaminases (therefore need to monitor LFT), hepatic fibrosis, cirrhosis
  • Lungs: Fibrosis, pneumonitis
  • Haem: bone marrow suppression/myelosuppression, leukopenia
  • Derm: photosensitivity, TEN, SJS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

[csDMARD - Methotrexate]

Mechanism of side effects

A

Mechanism: attributed to minor action, at higher dose and long term treatment

MTX inhibits DHFR, reduces levels of tetrahydrofolate and thus decreases synthesis of purines and pyrimidines.

This inhibition leads to a decrease in the production of DNA, RNA and certain amino acids, ultimately disrupting the growth and proliferation of rapidly dividing cells, such as those found in the bone marrow and the walls of GIT, which causes bone marrow suppression and GI disturbances.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

[csDMARD - Methotrexate]

How to keep side effects to a minimum?

A

Concomitant folic acid 5mg/week or folinic acid given 12-24h after methotrexate, can decrease MTX toxicity

Rescue therapy of methotrexate

Folic acid, a synthetic form of the naturally occurring vit B9, helps prevent MTX induced SE by counteracting the reduced levels of tetrahydrofolate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

[csDMARD - Methotrexate]

Difference b/w folic acid and folinic acid

A

Folic acid / Folate

  • Cheaper and more commonly used
  • However, require high doses as it does not efficiently rescue toxicity
  • Folic acid must be converted by DHFR into N5N10-Methylene-FH4 that is essential for cell proliferation (it does not bypass DHFR activity)

Folinic acid (N5-formyl-FH4)

  • More expensive
  • But more efficient at rescuing MTX toxicity
  • Rapidly converted to N5N10-Methylene-FH4 without DHFR activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

[csDMARD - Methotrexate]

(IC16) Contraindications

A
  • Preexisting liver disease
  • Immunodeficient syndrome
  • Blood dyscrasias

Other precautions/may not prescribe (from the video):

  • Liver cirrhosis
  • Certain lung conditions
  • Pregnant or trying to get pregnant
  • Man trying to get someone pregnant
  • Significant anemia
  • Low WBC
  • Breastfeeding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

[csDMARD - Methotrexate]

(IC16) Dose adjustment with hepatic or renal impairment

A

AST/ALT > 3x ULN: 75% of dose

CrCl <50ml/min: 50% of dose

CrCl <30ml/min: avoid use

MTX is 80% excreted renally unchanged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

[csDMARD - Methotrexate]

(IC16) DDIs

A
  • NSAIDs/COX-2 inhibitors (incr serum conc. of MTX)
  • PPI
  • Probenecid
  • Vaccines
  • Alcohol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

[csDMARD - Methotrexate]

(IC16) Use in pregnancy

A

Teratogenic, embro-fetal toxicity

(exclude pregnancy before starting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

[csDMARD - Methotrexate]

(IC16) Monitoring (side effects and labs)

A

Side effects:

  • Lung: SOB, cough
  • GI: N/V, mouth sores, diarrhea
  • Liver: jaundice
  • Dermatologic toxicity
  • Infections

Labs:

  • FBC
  • LFT (AST, ALT, albumin, bilirubin) - incr transminases, also may affect dosing
  • SCr (dose adjustment when CrCl <50ml/min, avoid use when CrCl <30ml/min)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

[csDMARD - Sulfasalazine]

MOA

A

Unknown, but poorly absorbed so may be mediated by effect in gut microflora, leading to changes in immune response:

  • Decreased IgA and IgM rheumatoid factors
  • Suppression of T and B cells, and macrophages
  • Decrease in inflammatory cytokines (e.g., IL-1B, TNF, IL-6)
  • (IC16) Modulates leukotrienes, inhibits TNF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

[csDMARD - Sulfasalazine]

Metabolism

A

Metabolized to sulfapyridine (active) + 5-aminosalicylic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

[csDMARD - Sulfasalazine]

Side effects

A
  • GI: Nausea and vomiting, dyspepsia
  • CNS: Headache, dizziness
  • Derm: Rash
  • Hemolytic anemia
  • Neutropenia
  • Reversible infertility in men

(IC16)

  • Genitourinary: Oligospermia (reversible), urine discoloration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

[csDMARD - Sulfasalazine]

(IC16) Contraindications

A
  • Sulfonamide allergies
  • Caution in G6PD deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

[csDMARD - Sulfasalazine]

(IC16) DDIs

A
  • Iron
  • Antibiotics
  • Warfarin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

[csDMARD - Sulfasalazine]

(IC16) Pregnancy Status

A

B, may use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

[csDMARD - Sulfasalazine]

(IC16) Monitoring: side effects and labs

A

Side effects

  • N/V
  • Rash
  • Infection

Lab

  • FBC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

[csDMARD - Leflunomide]

MOA

A

Inhibits dihydroorotate dehydrogenase

  • Decrease in pyrimidine synthesis and growth arrest at G1 phase
  • Inhibit T cell proliferation and B cell autoantibody production
  • Inhibit NF-kB activation pro-inflammatory pathway

DHODH plays a key role in the de novo synthesis of the pyrimidine

(IC16): decrease lymphocyte action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

[csDMARD - Leflunomide]

Metabolism

A

Rapidly converted to active metabolite, teriflunomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

[csDMARD - Leflunomide]

Side effects

A
  • GI: Diarrhea, nausea
  • Liver: incr transaminases (elevation of liver enzymes)
  • Derm: Alopecia, skin rash
  • CNS: headache
  • Haem: myelosuppression
  • Weight gain
  • Teratogenic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

[csDMARD - Leflunomide]

(IC16) Contraindication

A
  • Preexisting liver disease
  • ALT > 2x ULN
  • Immunodeficient states
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

[csDMARD - Leflunomide]

Half-life, implications

A

Leflunomide has very long half-life (detectable years after last dosing)

  • Cholestyramine (bile salt binding resin) is used to wash-out the drug (e.g., before pregnancy - since it is teratogenic)

If using Leflunomide, then cholestyramine is a drug interaction (IC16)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

[csDMARD - Leflunomide]

(IC16) Dose adjustment in liver impairment

A

ALT > 2x ULN: avoid use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

[csDMARD - Leflunomide]

(IC16) Pregnancy status

A

Teratogenic

(exclude pregnancy before starting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

[csDMARD - Leflunomide]

(IC16) Monitor SEs and Labs

A

Side effects:

  • Diarrhea
  • Hair loss
  • Jaundice
  • Infection

Labs:

  • FBC
  • LFTs (AST, ALT, albumin, bilirubin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

[csDMARD - Hydroxychloroquine]

MOA

Hydroxychloroquine is an anti-malarial agent

A
  • Effective anti-inflammatory agent (but least potent DMARD)
  • Reduced MHC Class II expression and antigen-presentation, (IC16) inhibit complement-dependent antigen-antibody reactions
  • Reduced TNF-a and IL-1, and cartilage resorption
  • Antioxidant activity
  • (IC16) inhibit locomotion of neutrophils, chemotaxis of eosinophils
30
Q

[csDMARD - Hydroxychloroquine]

Side effects

A
  • Nausea and vomiting
  • Stomach pain
  • CNS: headache, dizziness
  • Hair loss
  • Ophthalmic: Ocular toxicity, retinopathy
  • Derm: photosensitivity, hyperpigmentation
  • Metabolic: hypoglycemia
  • Neuropsychiatric symptoms
  • CVS: QT prolongation

Best tolerability out of the DMARDs

31
Q

[csDMARD - Hydroxychloroquine]

(IC16) Contraindications

A
  • Preexisting retinopathy
  • Caution in G6PD deficiency
32
Q

[csDMARD - Hydroxychloroquine]

(IC16) Pregnancy status

A

C

33
Q

[csDMARD - Hydroxychloroquine]

(IC16) Monitoring

A

Eye exam (ophthalmoscopy)

34
Q

[tsDMARD - Tofacitinib]

MOA

A

Non-selective JAK inhibitor, block JAK/STAT activation of gene transcription, thereby blocking cytokine production

  • binds to JAK proteins inside cells to prevent JAKs from transphosphorylating the associated cytokine and growth factor receptor
35
Q

[tsDMARD - Tofacitinib]

Dosage form

A

Small molecule kinase inhibitors, administered orally

36
Q

[tsDMARD - Tofacitinib]

What is another indication that Tofacitinib is also approved for?

A

Psoriatic arthritis (PsA)

37
Q

[tsDMARD - Tofacitinib]

Side effects

A
  • Cytopenia: including neutrophils, lymphocytes, platelets, NK cells
  • Immunosuppression: opportunistic infections, incr risk of herpes zoster infection esp in asian popln
  • Anemia (bc tsDMARDs can affect JAK2 activation by erythropoietin)
  • Hyperlipidemia (metabolic): incr in total, LDL, HDL, cholesterol, and triglycerides (bc JAK-STAT pathway involved in lipid pathway and control) => monitor lipid panel
38
Q

[tsDMARD - Tofacitinib]

Can tofacitinib be combined with csDMARDs or bDMARDs?

A
  • Can combine with MTX for mod-severe RA
  • tsDMARD cannot be combined with bDMARD => risk of additive effects, high risk of immunosuppression and opportunistic infections
39
Q

[tsDMARD - Tofacitinib]

Tofacitinib carries high risk for:

A

Tofacitinib carries high risk for major adverse cardiovascular events (MACEs) and malignancy (for individuals with the risk factors)

Note that bDMARD and tsDMARD carry similar risk for malignancy

tsDMARD along with IL-6 inhibitor, Tocilizumab, also carries risk for thrombosis and gastrointestinal perforation

40
Q

[tsDMARD - Tofacitinib]

What are some risk factors for cardiovascular events and malignancies that must be considered when intending to prescribe a JAK-inhibitor?

A

CVD risk factors:

  • Age >65
  • Hx of current or past smoking
  • Other CVD risk factors: diabetes, obesity, hypertension

Malignancy risk factors:

  • Other risk factors for malignancy: current of hx of malignancy other than successfully treated NMSC

Risk factors for thromboembolic events:

  • Risk factors for thromboembolic events (hx of MI, HF, cancer, inherited blood clotting disorders, hx of blood clots)
  • Pts taking combined hormonal contraceptives or HRT
  • Pts undergoing major surgery
  • Pts who are immobile
41
Q

[tsDMARD - Tofacitinib]

Risk factors for gastrointestinal perforation

A
  • Diverticulitis
  • > 65y
  • Glucocorticoid use
  • NSAID use
42
Q

[bDMARD]

Why are bDMARDs tried before tsDMARD?

A

bDMARDs are more specific and selective for certain cytokine pathways, hence less risk of broad-spectrum adverse effects compared to tsDMARDs

43
Q

[bDMARD]

Generally explain what are bDMARDs?

A
  • made by molecular biologic techniques
  • administered via SC injection or IV infusion
  • binds to cytokines or their receptors to downregulate/inhibit their function, thereby reducing immune and inflammatory response
44
Q

[bDMARD - TNF signaling blockers]

Name the TNF signaling blockers

A

Infliximab, Adalimumab, Golimumab, Etanercept

(From most to least immunogenic)

45
Q

[bDMARD - TNF signaling blockers]

Compare the MOA of Infliximab, Adalimumab, Golimumab, and Etanercept

A

Infliximab, Adalimumab, Golimumab:

  • Chimeric / Recombinant human IgG1 that binds to TNF-a

Etanercept:

  • Recombinant TNFR2-IgG1-Fc protein (decoy TNFR2 receptor IgG1 fusion protein) that intercepts, and binds to TNF-a, TNF-B, and lymphotoxin-A
  • NOT a monoclonal antibody
46
Q

[bDMARD - TNF signaling blockers]

Compare the administration of Infliximab, Adalimumab, Golimumab, and Etanercept

A

Infliximab: IV infusion

Adalimumab: SC (may self-administer)

Golimumab: IV/SC

Etanercept: SC (may self-administer)

47
Q

[bDMARD - TNF signaling blockers]

Compare the half-lives of Infliximab, Adalimumab, Golimumab, and Etanercept

A

Infliximab: 8-9.5 days

Adalimumab: 14 days

Golimumab: 12 +/- 3 days

Etanercept: 70h

48
Q

[bDMARD - TNF signaling blockers]

Side effects

A
  • Respiratory infection
  • Skin infection
  • Increased risk of lymphoma
  • Optic neuritis
  • Exacerbation of multiple sclerosis
  • Leukopenia
  • Aplastic anemia

Immunocompromised

49
Q

[bDMARD - TNF signaling blockers]

(IC16) Contraindication

A

NYHA Class III and IV Heart Failure

50
Q

[bDMARD - IL1 signaling blockers]

Which drug?

A

Anakinra

51
Q

[bDMARD - IL1 signaling blockers]

MOA

A

Anakinra is a recombinant IL-1 receptor antagonist, binds to IL-1 receptor and blocks signaling

It is less effective than TNF signaling blockers

In normal circumstances, endogenous IL-1 receptor antagonist protein regulates the IL receptor function by inhibiting it

52
Q

[bDMARD - IL1 signaling blockers]

Protein structure in comparison to endogenous IL-1 receptor antagonist

A

Differs from sequence of the endogenous protein by one methionine added to the N-terminus and not being glycosylated (no PTM)

53
Q

[bDMARD - IL1 signaling blockers]

Dosage form of Anakinra

A

SC

54
Q

[bDMARD - IL1 signaling blockers]

Side effects

A
  • Infections
  • Injection site reactions
55
Q

[bDMARD - IL6 signaling blockers]

Which drug?

A

Tocilizumab

56
Q

[bDMARD - IL6 signaling blockers]

MOA

A

Tocilizumab is a humanized mAb binds irreversibly at the IL-6Ra chain, prevents binding of IL-6 to IL-6Ra and homodimerization of IL-6RB signaling

57
Q

[bDMARD - IL6 signaling blockers]

Dosage form of Tocilizumab

A

IV

58
Q

[bDMARD - IL6 signaling blockers]

Side effects

A
  • Infections
  • Skin eruptions
  • Stomatitis
  • Fever
  • Neutropenia
  • Increase in ALT/AST
  • Hyperlipidemia
59
Q

[bDMARD - IL6 signaling blockers]

CYP interactions

A

NOT the typical CYP interaction, because biologics are cleared by proteolytic enzymes, hence we would not expect to see interaction with liver CYP enzymes

  • IL-6 reduces expression of CYP450 enzymes
  • Hence Tocilizumab which inhibits IL-6 receptors, would increase the expression of CYP450 enzymes
  • Indirectly causes decrease serum concentration of drugs that are CYP450 substrates (include CYP450, 3A4, 1A2, 2C9 substrates)
60
Q

[bDMARD - IL6 signaling blockers]

Tocilizumab carries risk of:

A

IL-6 inhibitor, Tocilizumab, along with tsDMARD carries risk for thrombosis and gastrointestinal perforation

61
Q

[bDMARD - IL6 signaling blockers]

Due to risk of thrombosis, Tocilizumab should be avoided in:

A

pt with history of thrombotic events

62
Q

[bDMARD - IL6 signaling blockers]

Risk factors for gastrointestinal perforation

A
  • Diverticulitis
  • > 65y
  • Glucocorticoid use
  • NSAID use
63
Q

[bDMARD - CTLA4-FcLgG1]

Which drug?

A

Abatacept

64
Q

[bDMARD - CTLA4-FcLgG1]

MOA

A

Abatacept is a recombinant fusion protein with CTLA4-FcLgG1, binds to CD80 and CD86 and prevents CD28 activation, thereby inhibiting T cell activation

suppress T cells

65
Q

[bDMARD - CTLA4-FcLgG1]

Dosage form

A

SC/IV

66
Q

[bDMARD - CTLA4-FcLgG1]

Side effects

A
  • Respiratory infection in COPD
  • Increase lymphoma incidence
67
Q

[bDMARD - Anti-CD20]

Which drug?

A

Rituximab

68
Q

[bDMARD - Anti-CD20]

MOA

A

Rituximab is a chimeric mAb IgG1 directed at CD20 on pre- and mature B cells, depletes CD20+ B cells, (induce killing of normal and malignant B cells that express CD20); blocks antigen presentation, autoantibody, and cytokine level

69
Q

[bDMARD - Anti-CD20]

Dosage form

A

IV Rituximab

70
Q

[bDMARD - Anti-CD20]

Side effects

A
  • Rash in first dose
  • Respiratory infection in COPD
71
Q

[bDMARD - Anti-CD20]

Rituximab also report risk of:

A

Gastrointestinal perforation (but mainly IL-6 inhibitor, Tocilizumab and tsDMARD tofacitinib)

  • Evaluate abdominal pain or vomiting

3154 MSK (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions